Tamoxifen

Property	Information
Drug Name	Tamoxifen
FDA Approval	Yes (for breast cancer treatment)
Used for	Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C
Clinical Trial Phase	Phase II clinical trials and retrospective studies for GBM
Clinical Trial Explanation	Not specified
Common Side Effects	Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain
OS without	Not specified
OS with	Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics
PFS without	Not specified
PFS with	In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.

From Ben Williams Book: Not specified

Loading comments...